Aperture Sectors › Healthcare & Life Sciences › Biomanufacturing & synthetic biology
Biomanufacturing & synthetic biology funding
Biomanufacturing & synthetic biology
A sub-sector of Healthcare & Life Sciences. Each company counts once, in its main sub-sector.
14 rounds, $95M raised by 14 companies, Jan 2, 2023 to Nov 14, 2026, 0% of Healthcare & Life Sciences capital. Top three companies: Baiyin Biotech 31%, Allozymes 16%, Rongrui Technology 15%.
| Company | HQ | Capital raised | Rounds | Exit |
|---|---|---|---|---|
| Baiyin Biotech | China | $30M | 1 | — |
| Allozymes | Singapore | $15M | 1 | — |
| Rongrui Technology | China | $14M | 1 | — |
| Weiyuan Biotech | China | $14M | 1 | — |
| baCta | France | $8.1M | 1 | — |
| Rubi | United States | $7.5M | 1 | — |
| ChemT Biotechnology | Singapore | $4M | 1 | — |
| Differential Bio | Germany | $2.2M | 1 | — |
| Cellarim Labs | India | $660K | 1 | — |
| bitBiome | Japan | $0 | 1 | — |
| Lemnisca | India | $0 | 1 | — |
| ReactWise | United Kingdom | $0 | 1 | — |
| Prolific Machines | United States | $0 | 1 | — |
| BioRaptor | Israel | $0 | 1 | — |
| Company | Amount | Stage | Announced |
|---|---|---|---|
| Baiyin Biotech | $30M | Series A | Oct 22, 2026 |
| Allozymes | $15M | Series A | May 3, 2024 |
| Rongrui Technology | $14M | Pre-A | Jun 27, 2025 |
| Weiyuan Biotech | $14M | Pre-A | Aug 19, 2025 |
| baCta | $8.1M | Seed | Mar 3, 2026 |
| Rubi | $7.5M | Unlabeled | Mar 17, 2026 |
| ChemT Biotechnology | $4M | Seed | Jun 22, 2026 |
| Differential Bio | $2.2M | Pre-Seed | Mar 26, 2025 |
| Cellarim Labs | $660K | Seed | Dec 17, 2025 |